NGN-101 is under clinical development by Neurogene and currently in Phase II for Batten Disease. According to GlobalData, Phase II drugs for Batten Disease have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NGN-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NGN-101 overview

NGN-101 is under development for the treatment of battens disease. It is administered through intracerebroventricular (ICV) and intravitreal (IVT) routes of administration. It acts by targeting Ceroid Lipofuscinosis Neuronal Protein 5 (CLN5). The therapy comprises of an adeno-associated virus (AAV) expressing healthy copy of Ceroid Lipofuscinosis Neuronal Protein 5 (CLN5).

Neurogene overview

Neurogene, formerly Neoleukin Therapeutics Inc., is a biopharmaceutical company that develops next-generation immunotherapies to treat immunological disorders. The company’s lead drug candidate NL-201 is a combined IL-2 and IL-15 protein therapeutic used as an agonist in the treatment of cancer immunotherapy. Neoleukin Therapeutics serves in therapeutic areas of rheumatoid arthritis, inflammatory bowel disease, asthma, multiple sclerosis, atopic dermatitis, and solid tumors. Neurogene is headquartered in Seattle, Washington, the US.

For a complete picture of NGN-101’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.